Your browser doesn't support javascript.
loading
Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study.
Gallop, Katy; Hall, Rebekah; Watt, Michael; Squirrell, Daniel; Branscombe, Neil; Arnetop, Sofie; Lloyd, Andrew.
Afiliação
  • Gallop K; Acaster Lloyd Consulting Ltd, London, United Kingdom.
  • Hall R; Acaster Lloyd Consulting Ltd, London, United Kingdom.
  • Watt M; AstraZeneca UK Ltd., London, United Kingdom.
  • Squirrell D; AstraZeneca UK Ltd., London, United Kingdom.
  • Branscombe N; AstraZeneca UK Ltd., Cambridge, United Kingdom.
  • Arnetop S; AstraZeneca Ltd. Gothenburg, Sweden.
  • Lloyd A; Acaster Lloyd Consulting Ltd, London, United Kingdom.
J Health Econ Outcomes Res ; 11(2): 20-28, 2024.
Article em En | MEDLINE | ID: mdl-39071729
ABSTRACT

Background:

Pre-exposure prophylaxis (PrEP) for COVID-19 provides additional protection, beyond vaccines alone, for individuals who are immunocompromised (IC). This may reduce the need for preventative behavioral modification, such as shielding-a behavioral restriction limiting an IC individual to minimize face-to-face interactions and/or crowded places. Therefore, PrEP may improve psychosocial well-being and health-related quality of life (HRQoL) for individuals with IC conditions.

Objective:

To estimate the potential HRQoL and utility benefit of PrEP for prevention of COVID-19 in individuals with IC conditions who may not have an adequate response of full vaccination (and therefore are at "highest risk" of severe COVID-19) that can be used in future economic evaluations of preventative therapies against COVID-19.

Methods:

Vignettes describing HRQoL associated with 2 pre-PrEP states (shielding and semi-shielding behavioral restrictions) and a post-PrEP state were developed from a literature review and tested through interviews with clinicians (n = 4) and individuals with IC conditions (n = 10). Vignettes were valued by a general population sample (N = 100) using a visual analog scale (VAS), time trade-off (TTO), and EQ-5D-5L. A sample of individuals with IC conditions (n = 48) valued their current HRQoL and a post-PrEP vignette using VAS and EQ-5D-5L.

Results:

Individuals with IC conditions reported a mean current EQ-5D-5L score of 0.574, and 0.656 for post-PrEP based on the vignette. PrEP would lead to behavior changes for 75% (30/40) of individuals with IC conditions and an emotional benefit for 93% (37/40) of individuals with IC conditions. Mean values from the general population valuation based on EQ-5D-5L ranged from 0.606 ("shielding") to 0.932 ("post-PrEP").

Conclusion:

This study quantified the expected health state utility benefit of reduced psychosocial burden and behavioral restriction. PrEP would potentially result in a utility gain between 0.082 and 0.326, dependent on valuation approach and expected change in behavioral restrictions, leading to improvements in daily activities and emotional well-being.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Health Econ Outcomes Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Health Econ Outcomes Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido